Lasvic tablet (lascufloxacin oral) / Kyorin - LARVOL DELTA

Adult Hospitalized Mycoplasma Cases in a Tertiary Hospital in Japan. (PubMed, Infect Drug Resist) - "He was treated with sulbactam/ampicillin drip infusion and oral administration of minocycline for 2 weeks, and improved. All hospitalized adult patients with mycoplasma pneumonia were treated with antibiotics, such as minocycline and fluoroquinolone, along with corticosteroid co-administration, and all of them ultimately improved, although the chest X-ray findings varied. Antibiotics other than macrolides and corticosteroids may be an effective regimen for the treatment of severe mycoplasma pneumonia with potential macrolide resistance."

Journal • Acute Kidney Injury • Aplastic Anemia • Cough • Hematological Disorders • Infectious Disease • Nephrology • Novel Coronavirus Disease • Oncology • Pneumonia • Pulmonary Disease • Renal Disease • Respiratory Diseases

Efficacy and Safety of Intravenous-to-Oral Lascufloxacin Switch Therapy in Community-Onset Pneumonia: A Single-Arm, Open-Label Clinical Trial. (PubMed, Cureus) - "Switch therapy using LSFX presented high efficacy and acceptable safety profiles against mild-to-moderate severity of COP. This strategy of using the same drug in both intravenous and oral formulations is quite innovative. LSFX may potentially emerge as one of the preferred options for treating COP."

Clinical • Journal • Hepatology • Infectious Disease • Liver Failure • Pneumonia • Respiratory Diseases

Temporal effects of lascufloxacin on human gut and salivary microbiota: analysis using next-generation sequencing method. (PubMed, J Infect Chemother) - "We elucidated that LSFX administration differentially affected the gut and salivary microbiota; however, the richness and beta diversity recovered within 28 days."

Biomarker • Journal • Next-generation sequencing • Infectious Disease • Pneumonia • Respiratory Diseases

Efficacy and safety of lascufloxacin for nursing- and healthcare-associated pneumonia: A single-arm, open-label clinical trial. (PubMed, J Infect Chemother) - "Oral LSFX is an acceptable treatment option for moderate NHCAP in elderly patients who can take oral medications."

Journal • Infectious Disease • Pneumonia • Respiratory Diseases

Evaluation of efficacy and safety of Lascufloxacin tablet for Nursing and Healthcare-Associated Pneumonia: single-arm, open-label clinical trial (APSR 2023) - No abstract available

Clinical • Infectious Disease • Pneumonia • Respiratory Diseases

Evaluation of efficacy and safety of lascufloxacin for nursing and healthcare associated pneumonia: single-arm, open-label clinical trial: A study protocol. (PubMed, Medicine (Baltimore)) - "NHCAP is a common pneumonia in clinical settings and a notable pneumonia whose mortality is high compared to community-acquired pneumonia. The present study showed the efficacy and safety of LSFX against NHCAP, which could lead to a larger number of therapeutic options for NHCAP."

Journal • Infectious Disease • Pneumonia • Respiratory Diseases

Pharmacokinetic study of lascufloxacin in non-elderly healthy men and elderly men. (PubMed, J Infect Chemother) - "After single-dose oral administration of LSFX 200 mg (capsules) to six elderly people in fasting state, its pharmacokinetic parameters were similar to those in non-elderly people, with no significant safety concerns. Therefore, adjustment of dosage and administration was considered to be unnecessary for LSFX administration to elderly individuals."

Clinical • Journal • PK/PD data